“Advanced Brain Therapies Through Innovation” 

CarThera® designs and develops innovative medical devices using the therapeutic potential of ultrasound to significantly improve the efficacy, comfort, and cost of treating a range of medical conditions.

CarThera® has focused on the treatment of brain tumors for the first applications of its innovative medical devices. CarThera’s devices are developed by a multidisciplinary team of medical doctors, biologists, and physicists. This multidisciplinary effort takes into account, from the early stages of development, the needs of both patients and physicians, and leads to innovative solutions.

The medical devices developed by CarThera originate from the work of Dr. Alexandre Carpentier, a neurosurgeon at the University Hospital Pitié-Salpêtrière in Paris, France. They are designed to respond to unmet clinical needs.


The two medical devices currently in development are designed to be used during outpatient procedures for the thermal ablation of brain tumors (SonoProbe) and for improving the efficacy of chemotherapy (SonoCloud®).

Both devices are innovative at multiple levels: 

Biologically — They employ the use of new tissue-ultrasound interactions. 

Clinically — They use interventional MRI procedures for the brain. 

Technologically — They use advanced technology for miniaturization. 

Organizationally — They open the possibility of new methods of outpatient care.




Pr Carpentier Interview  / Autrement Editions – may 2011.




« A new vision of surgery »

“I have always been interested in the development of new surgical technologies. Even though current surgical techniques provide an immense benefit to patients, I’m convinced that we can do even better, with the development of techniques that decrease both invasiveness and expense.  My medical objective is a bit idealistic: I envision surgery as a convergence of medical expertise, advanced materials, physical principles, and computational power. Such a convergence will allow for treatments with better efficacy and security, with diminished morbidity, under local anaesthesia, and on an outpatient basis. It may appear unfeasible, but we are on the way to success: We now have proof of concept and efficacy in pre-clinical studies for our two technologies under development.”


  • unnamed-2

  • News CarThera

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.

    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.